Preferential Selectivity of Inhibitors with Human Tau Protein Kinase Gsk3𝜷 Elucidates Their Potential Roles for Off-Target Alzheimer’s Therapy

Table 2

Percentage identity, similarity, and RMSD values (for the overlapping number of atoms).

	GSK3β	CDK5	P38	ERK1/2	JNK	CK1d	DYRK1A	AKT	PKA
CDK5	^#35.6%; ^@66.0%; *1.25 (238)	—	—	—	—	—	—	—	—
P38	32.3%; 62.0%; *1.45 (221)	36.4%; 64.9%; *1.52 (202)	—	—	—	—	—	—	—
ERK1/2	32.8%; 64.5%; *1.43 (252)	37.6%; 68.0%; *1.42 (233)	49.0%; 77.4%; *1.60 (277)	—	—	—	—	—	—
JNK	28.0%; 54.8%; *1.59 (238)	35.4%; 64.3%; *1.61 (228)	47.7%; 75.3%; *1.65 (265)	43.1%; 73.8%; *1.46 (287)	—	—	—	—	—
CK1d	25.3%; 49.6%; *1.64 (205)	22.8%; 48.1%; *1.60 (200)	25.6%; 54.0%; *1.72 (167)	29.5%; 50.4%; *1.75 (195)	24.6%; 50.8%; *1.76 (188)	—	—	—	—
DYRK1A	28.4%; 53.2%; *1.29 (253)	30.4%; 7.5%; *1.34 (243)	29.1%; 53.6%; *1.52 (218)	28.3%; 57.1%; *1.39 (246)	28.9%; 52.3%; *1.72 (247)	24.5%; 51.8%; *1.57 (213)	—	—	—
AKT	27.0%; 48.4%; *1.55 (222)	25.4%; 57.4%; *1.47 (214)	26.1%; 56.7%; *1.61 (205)	22.8%; 53.1%; *1.48 (231)	26.3%; 52.5%; *1.64 (221)	25.8%; 54.5%; *1.68 (207)	26.0%; 56.4%; *1.36 (230)	—	—
PKA	26.4%; 59.2%; *1.56 (213)	23.4%; 58.9%; *1.50 (207)	26.6%; 59.4%; *1.65 (183)	24.1%; 53.9%; *1.65 (214)	26.3%; 52.9%; *1.72 (194)	26.1%; 53.8%; *1.76 (207)	26.0%; 57.1%; *1.50 (219)	45.6%; 77.2%; *1.21 (292)	—
PKC	24.8%; 51.8%; *1.52 (223)	27.8%; 61.9%; *1.45 (214)	27.9%; 56.4%; *1.65 (203)	23.9%; 56.2%; *1.68 (228)	24.6%; 50.8%; *1.82 (221)	23.5%; 55.8%; *1.70 (208)	25.9%; 56.7%; *1.43 (224)	47.4%; 79.2%; *1.07 (285)	32.8%; 60.3%; *1.37 (279)

#Identity, ^@similarity, and *RMSD (total number of atoms involved).